FS Development (NASDAQ:FSDC) showed in an 8-K filing that its shareholders approved its combination with biotech firm Gemini Therapeutics, when at a special meeting earlier today only 100 shares redeemed.
This low redemption number is not too much of a surprise as the company opened at $13.06 ahead of the vote, and its share price has never dipped below its pro rata trust value. The filing did not include a timeline for the transaction’s close, but it should not be far off. GMNI is anticipated to be the new symbol for the share.
FS Development initially announced its $265.6 million deal with Gemini on October 15. Gemini is a clinical stage precision medicine company developing treatments for age-related macular degeneration (AMD) by developing drugging strategies that are matched to specific genetic mutations.
All measures on the special meeting’s ballot passed by wide margins with about 75.8% of shares participating. About 19% of shares voted against certain governance measures giving additional powers to the Board, however. For a full list of proposals and vote tallies, click HERE.
ADVISORS
- Jefferies LLC and SVB Leerink acted as co-lead private placement agents for FS Development Corp.
- Jefferies LLC also acted as lead financial and capital markets advisor to FS Development Corp.
- Goldman Sachs & Co. LLC acted as lead financial advisor to Gemini in the transaction.
- Stifel acted as additional capital markets advisor to Gemini.
- Goodwin Procter LLP acted as legal counsel to Gemini.
- White & Case LLP acted as legal counsel to FS Development Corp.


Globa Terra Acquisition Corporation (NASDAQ:GTERU) announced the pricing of its $152 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTERU”, Wednesday, July 9, 2025. The new SPAC plans to mount a search for a target in the agriculture, agtech or biotech sectors with an emphasis on water...
M3-Brigade V (NASDAQ:MBAV) has entered into a definitive agreement to combine with crypto treasury firm ReserveOne, assembling about $1 billion in equity funding. ReserveOne is setting up a diversified Bitcoin and digital asset treasury with a portion of its investments going towards blockchain infrastructure and venture raises. The combined company is expected to trade on...
At the SPAC of Dawn As the SPAC market has warmed in 2025, only 21 of the 70 SPACs (30%) that have IPO’d thus far have overfunded their trusts to draw in investors and none of these funded to more than 101%. By contrast, 87% of 2023 SPACs were overfunded – some to as high...
Emmis Acquisition Corporation (NASDAQ:EMISU) has filed for a $100 million SPAC to take a look at the manufacturing sector after a few unique wrinkles in their IPO process. Initial investors are set to receive one right to a 1/10 share in each unit purchased and the SPAC will have 18 months to complete a business...
Chenghe III (NASDAQ:CHEC.U) has filed for a $110 million SPAC to continue the team’s growing series while turning to a new underwriter. The new SPAC is offering investors a 1/2 warrant in each unit and no overfunding of the trust, but it will need to complete a business combination within 18 months of its IPO...